Thompson Siegel & Walmsley LLC Gilead Sciences, Inc. Transaction History

Thompson Siegel & Walmsley LLC

$6.24 Billion
Q2 2024

A detailed history of Thompson Siegel & Walmsley LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 67,384 shares of GILD stock, worth $5.94 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

67,384

Previous 67,300 0.12%

Holding current value

$5.94 Million

Previous $4.93 Million 6.23%

% of portfolio

0.07%

Previous 0.08%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$63.15 - $72.88 $5,304 - $6,121	84 Added 0.12%	67,384 $4.62 Million
Q4 2023 Feb 07, 2024	SELL	$73.27 - $83.09 $917,706 - $1.04 Million	-12,525 Reduced 15.69%	67,300 $5.45 Million
Q3 2023 Nov 08, 2023	SELL	$73.94 - $80.67 $1.46 Million - $1.6 Million	-19,775 Reduced 19.85%	79,825 $5.98 Million
Q2 2023 Aug 10, 2023	SELL	$76.01 - $86.7 $53,207 - $60,690	-700 Reduced 0.7%	99,600 $7.68 Million
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $1.16 Million - $1.32 Million	-15,000 Reduced 13.01%	100,300 $8.32 Million
Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $7.19 Million - $10.3 Million	115,300 New	115,300 $9.9 Million
Q3 2022 Oct 25, 2022	BUY	$59.54 - $68.01 $2.68 Million - $3.06 Million	45,000 Added 75.89%	104,300 $6.43 Million
Q2 2022 Jul 22, 2022	BUY	$57.72 - $65.01 $3.42 Million - $3.86 Million	59,300 New	59,300 $3.67 Million
Q4 2020 Feb 08, 2021	SELL	$56.65 - $64.55 $49,455 - $56,352	-873 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $456,062 - $573,419	-7,344 Reduced 89.38%	873 $55,000
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $8.74 Million - $10.1 Million	-120,817 Reduced 93.63%	8,217 $632,000
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $2.5 Million - $3.2 Million	-39,862 Reduced 23.6%	129,034 $9.65 Million
Q4 2019 Feb 07, 2020	SELL	$61.62 - $67.78 $430,662 - $473,714	-6,989 Reduced 3.97%	168,896 $11 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $184,091 - $203,205	-2,945 Reduced 1.65%	175,885 $11.1 Million
Q2 2019 Aug 12, 2019	SELL	$61.87 - $69.38 $729,880 - $818,475	-11,797 Reduced 6.19%	178,830 $12.1 Million
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $1.83 Million - $2.05 Million	29,220 Added 18.1%	190,627 $12.4 Million
Q4 2018 Feb 11, 2019	BUY	$60.54 - $79.0 $63,324 - $82,634	1,046 Added 0.65%	161,407 $10.1 Million
Q3 2018 Nov 08, 2018	BUY	$71.28 - $78.92 $57,950 - $64,161	813 Added 0.51%	160,361 $12.4 Million
Q2 2018 Aug 09, 2018	BUY	$64.88 - $75.68 $508,529 - $593,179	7,838 Added 5.17%	159,548 $11.3 Million
Q1 2018 May 08, 2018	SELL	$72.84 - $88.8 $945,463 - $1.15 Million	-12,980 Reduced 7.88%	151,710 $11.4 Million
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $1.41 Million - $1.65 Million	-19,790 Reduced 10.73%	164,690 $11.8 Million
Q3 2017 Nov 08, 2017	SELL	$72.11 - $85.47 $1.37 Million - $1.62 Million	-18,950 Reduced 9.32%	184,480 $14.9 Million
Q2 2017 Aug 09, 2017	BUY	N/A	203,430	203,430 $14.4 Million

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.

Account

Thompson Siegel & Walmsley LLC Gilead Sciences, Inc. Transaction History